Switching to
SCEMBLIX
In previously treated
Ph+ CML in chronic phase
Patient portrayal
Some patients with Ph+ CML in chronic phase may need to switch treatment. SCEMBLIX may be an option.
Has your doctor had to switch you from one tyrosine kinase inhibitor (TKI) for Ph+ CML in chronic phase to another? And perhaps yet another?
Your doctor may have made the switch because you did not respond to treatment. Or side effects became unmanageable. If this sounds familiar, it may be time to ask your doctor about SCEMBLIX.
SCEMBLIX results from a clinical trial:
More patients achieved MMR with SCEMBLIX than with Bosulif
SCEMBLIX is the first treatment for Ph+ CML in chronic phase to show superior efficacy, such as response rates, vs Bosulif® (bosutinib)* in a clinical trial.
In a clinical study among those who did not respond to or did not tolerate 2 or more prior TKIs for Ph+ CML in chronic phase:
Nearly twice as many patients achieved a major molecular response (MMR) with SCEMBLIX at 24 weeks than with Bosulif. The results were 25% for SCEMBLIX (40 of 157 patients) vs 13% for Bosulif (10 of 76 patients)
*Bosulif is a registered trademark of Pfizer Inc.
Nearly 40% of patients achieved MMR at 96 weeks
In the same clinical study among patients with Ph+ CML in chronic phase who were previously treated with 2 or more TKIs:
More than twice as many patients achieved MMR with SCEMBLIX at nearly 2 years (96 weeks) than with Bosulif. The results were 38% for SCEMBLIX (59 of 157 patients) vs 16% for Bosulif (12 of 76 patients)
In this clinical trial, the most common side effects reported (≥20%) with SCEMBLIX were nose/throat infections; pain in the muscles, bones, or joints; headache; and tiredness.
Three times fewer SCEMBLIX patients stopped treatment due to side effects
In the same clinical study, more patients taking SCEMBLIX were able to continue their treatment than those taking Bosulif. After nearly 2 years (96 weeks), 26% of patients taking Bosulif (20 of 76 patients) had to stop taking their medication due to side effects compared to 8% of those taking SCEMBLIX (12 of 156 patients).
Talk with your doctor about SCEMBLIX
When you have Ph+ CML in chronic phase, it’s important to be your own advocate. To help you have a productive conversation, download the Doctor Discussion Guide.
Common side effects of SCEMBLIX
The most common side effects of SCEMBLIX include:
muscle, bone, or joint pain
rash
tiredness
nose, throat, or sinus (upper respiratory tract) infections
headache
stomach-area (abdominal) pain
diarrhea
decreased white blood cell counts, platelet counts, and red blood cell counts
decreased blood calcium corrected levels
increased blood pancreas enzyme (lipase and amylase) levels
increased blood fat (cholesterol and triglycerides) levels
increased blood uric acid levels
increased blood liver enzyme levels
increased blood alkaline phosphatase levels
increased blood creatine kinase levels
Your doctor may change your dose, temporarily stop, or permanently stop treatment with SCEMBLIX if you have certain side effects.
SCEMBLIX may cause fertility problems in females. This may affect your ability to have a child. Talk to your doctor if this is a concern for you.
Be sure to review information about the serious and most common side effects of SCEMBLIX. Learn more
